NCT03035253 - A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

December 31, 2018

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

OMP-305B83

DRUG

FOLFIRI

Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.

DRUG

FOLFOX

Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.

Trial Locations (6)

Washington University School of Medicine Siteman Cancer Center, St Louis

Rocky Mountain Cancer Centers, Denver

Cancer Care & Hematology - Fort Collins, Fort Collins

University of Utah, Huntsman Cancer Institute, Salt Lake City

City of Hope National Medical Center, Duarte

University of Michigan Health System, Ann Arbor